This was the stock's third consecutive day of gains.

(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine ...

Results of 3 trials revealed that omitting transplant did not impact progression or survival outcomes for pediatric, ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive ...

Clinicians may one day be able to treat immune checkpoint inhibitor-related myocarditis without disrupting cancer therapy, findings from a cellular investigation showed.Individuals who die of immune ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

The Board also approved a Miss. State career center funded through the U.S. Department of Education Rehabilitation Services ...

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March ...

The two biggest questions for SCHD right now are 1) what’s caused it to underperform so badly, even within its category and 2) will those trends continue into 2025.